NeurologyLive

NeurologyLive™ provides both print and digital media resources tailored for healthcare professionals focused on treating neurological disorders. It delivers vital news and insights straight from leading medical conferences and experts in the field. This platform offers a comprehensive overview of the numerous new treatments being developed, showcasing their innovative mechanisms of action. As the need for neurology specialists continues to rise, NeurologyLive™ keeps its audience informed with the latest clinical trial outcomes, FDA approvals, groundbreaking research, and expert opinions.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#390731

United States

#163123

Health/Health Conditions and Concerns

#395

Traffic sources

Monthly visitors

Articles

Observed Differences in PIRA Definition Call for More Standardized Agreement on Term

1 day ago | neurologylive.com | Isabella Ciccone

Newly published in JAMA Neurology, a retrospective cohort study using MSBase registry data that compared 360 definitions of progression independent of relapse activity (PIRA) in patients with relapsing-remitting multiple sclerosis (MS) reported substantial differences in PIRA incidence and persistence depending on definition parameters.The study suggests that a proposed standardized definition could improve consistency and comparability across future MS research.1 Overall, the analysis...
A Mother’s Journey Through Diagnosis and Acceptance of Duchenne Muscular Dystrophy: Debra Miller

2 days ago | neurologylive.com | Debra Miller |Isabella Ciccone

CommentaryVideoMay 13, 2025Author(s):,Fact checked by:The chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]WATCH TIME: 4 minutes"As a mom, you lead with love and where that takes you is completely off the path that you thought you had.
The Role of Aging in Multiple Sclerosis Care

3 days ago | neurologylive.com | Marisa McGinley |Devon Conway |Moein Amin |Isabella Ciccone

WATCH TIME: 5 minutesThe 2025 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held February 27 to March 1, in West Palm Beach, Florida. This CE-accredited meeting featured a single track of scientific and clinical presentations focused on advancing research and treatment for multiple sclerosis (MS) and related disorders.
Interim Analysis Reveals Long-Term Efficacy and Safety of Pitolisant in Narcolepsy Types 1 and 2

3 days ago | neurologylive.com | Isabella Ciccone

Newly published Sleep Medicine, an interim analysis from a long-term, post authorization safety study European study reported that pitolisant (Wakix; Harmony Biosciences), an approved treatment for excessive daytime sleepiness (EDS) in pediatric patients with narcolepsy, demonstrated safety, tolerability and efficacy among patients with narcolepsy type 1 (NT1) and type 2 (NT2) after 42.6 months of follow-up.1 In this analysis, investigators included 370 patients with narcolepsy (mean age, 40...
AI and Machine Learning in MS: Promise and Practicality for Clinical Practice

3 days ago | neurologylive.com | Marisa McGinley |Devon Conway |Moein Amin |Isabella Ciccone

WATCH TIME: 9 minutesThe 2025 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held February 27 to March 1, in West Palm Beach, Florida. This CE-accredited meeting featured a single track of scientific and clinical presentations focused on advancing research and treatment for multiple sclerosis (MS) and related disorders.
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity

3 days ago | neurologylive.com | Isabella Ciccone

A recently published systematic review reported that serum neurofilament light chain (sNfL) levels were elevated in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), particularly during clinical attacks and in those with brain lesions, but had limited ability to predict relapse or differentiate MOGAD from related demyelinating diseases.1 Published in Multiple Sclerosis and Related Disorders, the review analyzed 23 original research articles comprising data...
Emerging Therapies and the Future of MS: Insights on BTK Inhibitors and CAR T-Cells

4 days ago | neurologylive.com | Marisa McGinley |Devon Conway |Moein Amin |Isabella Ciccone

WATCH TIME: 8 minutesThe 2025 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held February 27 to March 1, in West Palm Beach, Florida. This CE-accredited meeting featured a single track of scientific and clinical presentations focused on advancing research and treatment for multiple sclerosis (MS) and related disorders.
South Korea Nationwide Study Reveals Elevated Risk of Autoimmune Rheumatic Diseases in MS and NMOSD

4 days ago | neurologylive.com | Isabella Ciccone

A newly published analysis of national health data between 2010 and 2017 from the Korean National Health Insurance Service revealed that patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) had an increased risk of developing autoimmune rheumatic diseases (ARDs) compared with matched controls.1 Using diagnostic codes and registry information, researchers identified patients with MS and NMOSD and compared them with matched control groups at a 1:10 ratio...
NeurologyLive® Brain Games: May 11, 2025

5 days ago | neurologylive.com | Marco Meglio

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data

5 days ago | neurologylive.com | Marco Meglio

Newly announced findings from the phase 2 MAGNIFY trial (NCT05893537) showed that treatment with investigation zervimesine (Cognition Therapeutics), a small molecule agent, led to slower lesion growth in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) over an 18-month period.1 In the latest data update, patients on 200 mg of once-daily zervimesine, or CT1812, had 28.6% slower GA lesion growth on average when compared with those on placebo,...